(Q35212678)

7 August 2017

title

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies (English)

1 reference

7 August 2017

1 reference

5

C Robert

0 references

Christian H. Ottensmeier

object named as

C Ottensmeier

7

0 references

Richard Marais

object named as

R Marais

2

0 references

Paul Lorigan

object named as

P Lorigan

4

0 references

author name string

T Eisen

1

1 reference

7 August 2017

A Affolter

3

1 reference

7 August 2017

P Corrie

6

1 reference

7 August 2017

C Chevreau

8

1 reference

7 August 2017

D Chao

9

1 reference

7 August 2017

P D Nathan

10

1 reference

7 August 2017

T Jouary

11

1 reference

7 August 2017

M Harries

12

1 reference

7 August 2017

S Negrier

13

1 reference

7 August 2017

E Montegriffo

14

1 reference

7 August 2017

T Ahmad

15

1 reference

7 August 2017

I Gibbens

16

1 reference

7 August 2017

M G James

17

1 reference

7 August 2017

U P Strauss

18

1 reference

7 August 2017

S Prendergast

19

1 reference

7 August 2017

M E Gore

20

1 reference

7 August 2017

language of work or name

English

0 references

publication date

12 July 2011

1 reference

British Journal of Cancer

7 August 2017

published in

1 reference

7 August 2017

volume

105

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

353-359

1 reference

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Epidemiology of invasive cutaneous melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Sorafenib in advanced hepatocellular carcinoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Sorafenib in advanced clear-cell renal-cell carcinoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Improving the design of phase II trials of cytostatic anticancer agents

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Chemotherapy and targeted therapy combinations in advanced melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Improving outcomes in advanced malignant melanoma: update on systemic therapy

13 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

13 July 2018

https://api.crossref.org/works/10.1038%2FBJC.2011.257

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

B-RAF is a therapeutic target in melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Mutations of the BRAF gene in human cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

Optimal two-stage designs for phase II clinical trials

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

13 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.257

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.257

BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3172912

A population-based validation of the American Joint Committee on Cancer melanoma staging system

15 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21750549

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21750549

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

P504S expressing circulating prostate cells as a marker for prostate cancer

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2011.257

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/BJC.2011.257

1 reference

7 August 2017

1 reference

7 August 2017

1 reference